Medpace(US:MEDP)2026-02-10 15:02Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $708.5 million, a year-over-year increase of 32%, while full year 2025 revenue reached $2.53 billion, reflecting a 20% increase from 2024 [7][9] - EBITDA for Q4 2025 was $160.2 million, up 20% from $133.5 million in Q4 2024, with a full year EBITDA of $557.7 million, an increase of 16.1% [9][10] - Net income for Q4 2025 was $135.1 million, a 15.5% increase compared to $117 million in the prior year, with full year net income at $451.1 million, representing an 11.6% increase [10][11] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q4 increased by 39.1% year-over-year to $736.6 million, resulting in a net book-to-bill ratio of 1.04 [7][9] - Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase from the prior year [7][8] Market Data and Key Metrics Changes - The company reported a backlog conversion rate of 23.6% in Q4, with an expectation that approximately $1.9 billion of backlog will convert to revenue in the next 12 months [8][9] Company Strategy and Development Direction - The company views the overall business environment as adequate and improving, with continued opportunities for growth despite elevated cancellation rates [5][6] - There is an expectation for accelerated hiring in 2026, with a focus on mid to high single-digit growth in headcount to support business growth [17][18] Management's Comments on Operating Environment and Future Outlook - Management noted that cancellations were elevated in Q4, the highest level in over a year, but does not expect this trend to continue [5][6] - The company anticipates revenue growth in 2026 to be in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 [12][13] Other Important Information - The company repurchased 2.96 million shares for $912.9 million in 2025, with $821.7 million remaining under the share repurchase authorization program [11][12] - Management indicated that the impact of AI on productivity is expected to be gradual, with no immediate advantages anticipated in 2026 [55][56] Q&A Session Summary Question: What is embedded in your guidance for revenue growth excluding pass-throughs? - Management does not provide guidance on direct service revenue but expects reimbursable costs to be around 41%-42% of revenue in 2026 [16] Question: What do you expect headcount growth to be in 2026? - Management anticipates hiring in 2026 to be above 25 levels, in the mid to high single-digit growth area [18] Question: Can you unpack the business environment and RFP activity? - Management noted that RFPs were up slightly, but cancellations led to missing expectations [21] Question: Can you provide details on cancellations? - Cancellations were widespread, with no single large project responsible, and were particularly elevated in the metabolic area [27][28] Question: How do you view the competitive landscape? - Management does not perceive a significant change in the competitive dynamics, stating that the same competitors remain active in the space [63] Question: What are your thoughts on AI and its impact? - Management believes that while AI will bring changes, the benefits will take time to materialize, and there may be a net negative impact on staffing needs [55][56]